The Women's Health Initiative Studies (WHI) were designed to examine the effects of estrogen and progestin (E+P; Prempro) and estrogen alone (Premarin) in post-menopausal women. The authors of the WHI studies and the National Heart Lung and Blood Institute (NHLBI) concluded that E+P treatment increased the risks of coronary heart disease, invasive breast cancer, stroke and venous thromboembolism. The following paper contains a reevaluation of these studies based on the graphic analysis of their tabulated data. In contrast to the conclusions reached by the WHI and the NHLBI, I conclude that treatment of post-menopausal women with estrogen and progestin (Prempro) does not increase the risks of cardiovascular disease, invasive breast cancer, stroke or venous thromboembolism. I also disagree with the claim that an increased risk of stroke existed in women treated with estrogen alone.
References
1.
AndersonG. L., LimacherM., AssafA. R., BassfordT., BeresfordS. A., BlackH., BondsD., BrunnerR., BrzyskiR., CaanB., ChlebowskiR., CurbD., GassM., HaysJ., HeissG., HendrixS., HowardB. V., HsiaJ., HubbellA., JacksonR., JohnsonK. C., JuddH., KotchenJ. M., KullerL., LaCroixA. Z., LaneD., LangerR. D., LasserN., LewisC. E., MansonJ., MargolisK., OckeneJ., O'SullivanM. J., PhillipsL., PrenticeR. L., RitenbaughC., RobbinsJ., RossouwJ. E., SartoG., StefanickM. L., Van HornL., Wactawski-WendeJ., WallaceR., and Wassertheil-SmollerS. (2004). Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trialJama291, 1701–12.
2.
BraendleW, and KuhlH (2003) Stellungnahme zur Millionen-Frauenstudie und Brustkrebs. J Menopause3, 3–4.
3.
ChlebowskiR. T., HendrixS. L., LangerR. D., StefanickM. L., GassM., LaneD., RodaboughR. J., GilliganM. A., CyrM. G., ThomsonC. A., KhandekarJ., PetrovitchH., and McTiernanA. (2003). Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized TrialJama289, 3243–53.
4.
CoxDR (1972) Regression analysis and life tables. J R Stat. Soc.34, 187–200.
5.
CurbJ. D., PrenticeR. L., BrayP. F., LangerR. D., Van HornL., BarnabeiV. M., BlochM. J., CyrM. G., GassM., LepineL., RodaboughR. J., SidneyS., UwaifoG. I., and RosendaalF. R. (2006). Venous thrombosis and conjugated equine estrogen in women without a uterusArch Intern Med166, 772–80.
6.
DietelM., LewisM. A., and ShapiroS. (2005). Hormone replacement therapy: pathobiological aspects of hormone-sensitive cancers in women relevant to epidemiological studies on HRT: a mini-reviewHum Reprod20, 2052–60.
7.
FletcherS.W., and ColditzG. A. (2002). Failure of estrogen plus progestin therapy for preventionJama288, 366–8.
8.
GannP. H., and MorrowM. (2003). Combined hormone therapy and breast cancer: a single-edged swordJama289, 3304–6.
9.
GoodmanN, GoldzieherJ, and AyalaC (2003) Critique of the report from the writing group of the WHI. Menopausal Med10, 1–4.
10.
GrodsteinF., MansonJ. E., and StampferM. J. (2006). Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiationJ Womens Health (Larchmt)15, 35–44.
11.
HarmanS. M., NaftolinF., BrintonE. A., and JudelsonD. R. (2005). Is the estrogen controversy over? Deconstructing the Women's Health Initiative study: a critical evaluation of the evidenceAnn N Y Acad Sci1052, 43–56.
12.
HsiaJ., LangerR. D., MansonJ. E., KullerL., JohnsonK. C., HendrixS. L., PettingerM., HeckbertS. R., GreepN., CrawfordS., EatonC. B., KostisJ. B., CaralisP., and PrenticeR. (2006). Conjugated equine estrogens and coronary heart disease: the Women's Health InitiativeArch Intern Med166, 357–65.
13.
KarasRH, and ClarksonTB (2003) Considerations in interoperating the cardiovascular effects of hormone replacement therapy observed in the WHI: timing is everything. Menopausal Med10, 8–10.
14.
KellyP (2002). Recent HRT studies: the findings in perspective. San Francisco Medicine Magazine
15.
KoscielnyS., TubianaM., and ValleronA. J. (1985). A simulation model of the natural history of human breast cancerBr J Cancer52, 515–24.
16.
MachensK., and Schmidt-GollwitzerK. (2003). Issues to debate on the Women's Health Initiative (WHI) study. Hormone replacement therapy: an epidemiological dilemma?Hum Reprod18, 1992–9.
17.
MansonJ. E., HsiaJ., JohnsonK. C., RossouwJ. E., AssafA. R., LasserN. L., TrevisanM., BlackH. R., HeckbertS. R., DetranoR., StricklandO. L., WongN. D., CrouseJ. R., SteinE., and CushmanM. (2003). Estrogen plus progestin and the risk of coronary heart diseaseN Engl J Med349, 523–34.
18.
McDonoughP. G. (2002). The randomized world is not without its imperfections: reflections on the Women's Health Initiative StudyFertil Steril78, 951–6.
19.
MoherD., SchulzK. F., and AltmanD. (2001). The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trialsJama285, 1987–91.
20.
NaftolinF., TaylorH. S., KarasR., BrintonE., NewmanI., ClarksonT. B., MendelsohnM., LoboR. A., JudelsonD. R., NachtigallL. E., HewardC. B., HechtH., JaffM. R., and HarmanS. M. (2004). The Women's Health Initiative could not have detected cardioprotective effects of starting hormone therapy during the menopausal transitionFertil Steril81, 1498–501.
21.
National Cancer Institute. (2002). Experts weigh in on hormone therapy.www.cancer.gov
PedersenA. T., and OttesenB. (2003). Issues to debate on the Women's Health Initiative (WHI) study. Epidemiology or randomized clinical trials–time out for hormone replacement therapy studies?Hum Reprod18, 2241–4.
24.
RossouwJ. E., AndersonG. L., PrenticeR. L., LaCroixA. Z., KooperbergC., StefanickM. L., JacksonR. D., BeresfordS. A., HowardB. V., JohnsonK. C., KotchenJ. M., and OckeneJ. (2002). Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trialJama288, 321–33.
25.
ShapiroS. (2003). Risks of estrogen plus progestin therapy: a sensitivity analysis of findings in the Women's Health Initiative randomized controlled trialClimacteric6, 302–10; discussion 310–3.
26.
StefanickM. L., AndersonG. L., MargolisK. L., HendrixS. L., RodaboughR. J., PaskettE. D., LaneD. S., HubbellF. A., AssafA. R., SartoG. E., SchenkenR. S., YasmeenS., LessinL., and ChlebowskiR.T. (2006). Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomyJama295, 1647–57.
27.
TaubesG. (1995). Epidemiology faces its limitsScience269, 164–9.
28.
TurgeonJ. L., McDonnellD. P., MartinK. A., and WiseP. M. (2004). Hormone therapy: physiological complexity belies therapeutic simplicityScience304, 1269–73.
29.
von FournierD., WeberE., HoeffkenW., BauerM., KubliF., and BarthV. (1980). Growth rate of 147 mammary carcinomasCancer45, 2198–2207.
30.
Wassertheil-SmollerS., HendrixS. L., LimacherM., HeissG., KooperbergC., BairdA., KotchenT., CurbJ. D., BlackH., RossouwJ. E., AragakiA., SaffordM., SteinE., LaowattanaS., and MysiwW. J. (2003). Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trialJama289, 2673–84.
